Last updated on October 2017

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

Brief description of study

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of initial ZS therapy (10g TID).

Clinical Study Identifier: NCT02875834

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
Yao-shi, Japan
  Connect »